A Phase 2 interventional study of Ticagrelor and Placebo in Sickle Cell Disease, sponsored by AstraZeneca. Completed at 20 sites in 8 countries. Open to participants aged 18 Years to 30 Years. Per ClinicalTrials.gov, last updated 2018-12-19.
Sponsored by AstraZeneca · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 733 studies in Anemia, Sickle Cell with a site in United States — 134 open to participants now, 185 under way, 16 of them phase 3. Anemia, Sickle Cell · United States.
Among the 733 studies in Anemia, Sickle Cell with a site in United States, this one is the 127th largest by enrollment of the 559 interventional ones that give a count, is one of 38 that started in 2015, is one of 161 in phase 2, and was the 313th registered.
1,134 studies on the registry are indexed under Anemia, Sickle Cell; 238 are open to participants now.
Browse Anemia, Sickle Cell studies →134 of the 733 studies in Anemia, Sickle Cell with a site in United States are open now. Recruiting first, the newest first:
University of Maryland, Baltimore · Sites in United States
Ages 18–88
Mohsen Saidinejad · Sites in United States
Ages 5–20
St. Jude Children's Research Hospital · Sites in United States
Ages up to 22
Emory University · Sites in United States
Ages 8–18
University of Alabama at Birmingham · Sites in United States
Ages 18–50 · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 30 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
733 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 158 · Phase 2 228 · Phase 3 57 · Phase 4 20
First in 1984; this study’s year is marked. 38 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 87 is above the median of 40 across 769 interventional studies indexed under Anemia, Sickle Cell.
Median enrollment 31 across the 559 interventional studies, 100 across the 168 observational. Of the 506 that completed or were terminated, 207 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
168 of 733 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
AstraZeneca has 7 studies filed under Anemia, Sickle Cell — fewer than ten, so there is no comparison to draw.
57 of the studies in Anemia, Sickle Cell with a site in United States that are under way reach primary completion within a year, 7 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07247188Phase 3SanofiStudy of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease | 2027-01-07 |
| NCT04293185Phase 3bluebird bioA Study Evaluating Gene Therapy With BB305 Lentiviral Vector in Sickle Cell Disease | 2027-05 |
| NCT06989567Phase 3Asklepion Pharmaceuticals, LLCA Study of Intravenous L-Citrulline in Patients Aged 6-21 Years Old With Sickle Cell Disease Presenting to Emergency Departments in Acute Vaso-Occlusive Crisis | 2027-06 |
| NCT05329649Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD) | 2027-06-06 |
| NCT05477563Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease | 2027-06-09 |
Add all 57 to your calendar (.ics) → With an account.
Among the 733 studies in Anemia, Sickle Cell with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether ticagrelor is effective in reducing the number of days of pain, intensity of pain, and reducing the use of analgesics due to sickle cell disease
This is a randomised, double-blind, double-dummy, parallel-group, placebo-controlled, study evaluating 2 doses of ticagrelor in 90 patients aged 18 to 30 years, with sickle cell disease (SCD). Patients will be randomised to double-blind double-dummy treatment period in a 1:1:1 ratio (30 to each treatment group) to receive ticagrelor 10 mg twice daily (bid), or ticagrelor 45 mg bid, or placebo bid to determine the frequency of days with pain using an electronic diary (eDiary) every day. Approximately 180 patients will be enrolled. Patient will be followed for safety assessment during and after 2 weeks of treatment completion.
During the 16 week treatment period, patients will complete a daily eDiary concerning daily pain intensity, pain location, use of analgesics and absence from school or work. At the end of the study patients will be asked to rate the change in their sickle cell pain compared to the start of treatment. Platelet aggregation will be measured and reported as P2Y12 reaction units (PRU) pre-dose and 2 hours post-dose at week 4 and week 5 after treatment start. Pharmacokinetic (PK) parameters will be measured at 2 hours post-dose at week 4, and pre-dose and at 2 hours post-dose at week 5. Biomarkers will be assessed pre-dose at week 4, week 5 and week 8. During the study, patients will be evaluated for adverse events (AEs) including bleeding and vaso-occlusive crisis (VOC).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Ticagrelor
Drug: Ticagrelor
Drug: Placebo
Two arms: 1) 10 mg ticagrelor + 45 mg ticagrelor placebo or 2) 45 mg ticagrelor + 10 mg ticagrelor placebo. Drugs taken orally, twice a day (morning and evening, at least 12 hours apart) from randomization until the end of treatment.
10 mg ticagrelor placebo + 45 mg ticagrelor placebo. Drugs taken orally, twice a day (morning and evening at least 12 hours apart) from randomization until the end of treatment
Change in Proportion of Days With Pain Due to Sickle Cell Disease as Measured by an eDiary
To investigate the efficacy of 2 different doses of ticagrelor versus placebo in reducing the number of days with pain due to sickle cell disease.
Time frame: Baseline through Week 12
Average of the Daily Worst Pain Values Reported Via eDiary
To determine the efficacy of 2 different doses of ticagrelor versus placebo in reducing the intensity of pain due to sickle cell disease. Intensity of pain was recorded on an 11-point scale where 0 represented no pain and 10 represented the worst pain imaginable.
Time frame: Baseline through Week 12
Change in Proportion of Days With Analgesic Use Measured by an eDiary
To assess the efficacy of 2 different doses of ticagrelor versus placebo in reducing the use of analgesics by patients with sickle cell disease.
Time frame: Baseline through Week 12
Number of Major Bleeding or Clinically Relevant Non-major Bleeding Events (Patients)
To assess safety and tolerability of 2 different doses of ticagrelor versus placebo in patients with SCD
Time frame: Baseline through Week 12
Number of Major Bleeding or Clinically Relevant Non-major Bleeding Events (Events)
To assess safety and tolerability of 2 different doses of ticagrelor versus placebo in patients with SCD
Time frame: Baseline through Week 12
This study was conducted at 26 centers in 8 countries between 09 July 2015 and 16 November 2016.
| Milestone | PLACEBO 10MG BID + PLACEBO 45MG BID | TICAGRELOR 10MG BID + PLACEBO 45MG BID | TICAGRELOR 45MG BID + PLACEBO 10MG BID |
|---|---|---|---|
| Started | 30 | 27 | 30 |
| Completed | 28 | 24 | 27 |
| Not completed | 2 | 3 | 3 |
| Withdrew: Withdrawal by subject | 2 | 1 | 2 |
| Withdrew: Did not fulfill randomization criteria | 0 | 1 | 0 |
| Withdrew: Dev. of study-spec. withdrawal criteria | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 |
To investigate the efficacy of 2 different doses of ticagrelor versus placebo in reducing the number of days with pain due to sickle cell disease.
| Proportion of days with pain | PLACEBO 10MG BID + PLACEBO 45MG BID | TICAGRELOR 10MG BID + PLACEBO 45MG BID | TICAGRELOR 45MG BID + PLACEBO 10MG BID |
|---|---|---|---|
| Change in Proportion of Days With Pain Due to Sickle Cell Disease as Measured by an eDiary | -0.1802 ± 0.05453 | -0.1352 ± 0.05287 | -0.1001 ± 0.05233 |
To determine the efficacy of 2 different doses of ticagrelor versus placebo in reducing the intensity of pain due to sickle cell disease. Intensity of pain was recorded on an 11-point scale where 0 represented no pain and 10 represented the worst pain imaginable.
| Average daily worst pain rating | PLACEBO 10MG BID + PLACEBO 45MG BID | TICAGRELOR 10MG BID + PLACEBO 45MG BID | TICAGRELOR 45MG BID + PLACEBO 10MG BID |
|---|---|---|---|
| Average of the Daily Worst Pain Values Reported Via eDiary | 1.02 ± 1.106 | 1.15 ± 1.547 | 1.74 ± 2.277 |
To assess the efficacy of 2 different doses of ticagrelor versus placebo in reducing the use of analgesics by patients with sickle cell disease.
| Proportion of days with analgesic use | PLACEBO 10MG BID + PLACEBO 45MG BID | TICAGRELOR 10MG BID + PLACEBO 45MG BID | TICAGRELOR 45MG BID + PLACEBO 10MG BID |
|---|---|---|---|
| Change in Proportion of Days With Analgesic Use Measured by an eDiary | -0.1991 ± 0.08763 | -0.0799 ± 0.08540 | -0.1016 ± 0.08664 |
To assess safety and tolerability of 2 different doses of ticagrelor versus placebo in patients with SCD
| Number of patients | PLACEBO 10MG BID + PLACEBO 45MG BID | TICAGRELOR 10MG BID + PLACEBO 45MG BID | TICAGRELOR 45MG BID + PLACEBO 10MG BID |
|---|---|---|---|
| Patients with any bleeding events | 2 | 2 | 2 |
| Pts w/ any bleeding event requiring intervention | 2 | 1 | 2 |
To assess safety and tolerability of 2 different doses of ticagrelor versus placebo in patients with SCD
| Number of events | PLACEBO 10MG BID + PLACEBO 45MG BID | TICAGRELOR 10MG BID + PLACEBO 45MG BID | TICAGRELOR 45MG BID + PLACEBO 10MG BID |
|---|---|---|---|
| Total number of bleeding events | 2 | 2 | 2 |
| Maximum severity of bleeding event: Minor | 0 | 1 | 0 |
| Max sever. of bleed event: Clin-relevant nonmajor | 2 | 1 | 2 |
| Maximum severity of bleeding event: Major | 0 | 0 | 0 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PLACEBO 10MG BID + PLACEBO 45MG BID | — | 6/30 (20%) | 16/30 (53.3%) |
| TICAGRELOR 10MG BID + PLACEBO 45MG BID | — | 6/26 (23.1%) | 15/26 (57.7%) |
| TICAGRELOR 45MG BID + PLACEBO 10MG BID | — | 5/30 (16.7%) | 20/30 (66.7%) |
| Event | PLACEBO 10MG BID + PLACEBO 45MG BID | TICAGRELOR 10MG BID + PLACEBO 45MG BID | TICAGRELOR 45MG BID + PLACEBO 10MG BID |
|---|---|---|---|
| Sickle cell anaemia with crisisBlood and lymphatic system disorders | 3/30 | 5/26 | 3/30 |
| GastroenteritisInfections and infestations | 2/30 | 0/26 | 1/30 |
| Lower respiratory tract infectionInfections and infestations | 0/30 | 1/26 | 0/30 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/30 | 1/26 | 0/30 |
| HeadacheNervous system disorders | 0/30 | 1/26 | 0/30 |
| Acute chest syndromeRespiratory, thoracic and mediastinal disorders | 0/30 | 1/26 | 1/30 |
| ReticulocytopeniaBlood and lymphatic system disorders | 0/30 | 0/26 | 1/30 |
| Local swellingGeneral disorders | 1/30 | 0/26 | 0/30 |
| Hepatic ischaemiaHepatobiliary disorders | 1/30 | 0/26 | 0/30 |
| CellulitisInfections and infestations | 1/30 | 0/26 | 0/30 |
| Event | PLACEBO 10MG BID + PLACEBO 45MG BID | TICAGRELOR 10MG BID + PLACEBO 45MG BID | TICAGRELOR 45MG BID + PLACEBO 10MG BID |
|---|---|---|---|
| HeadacheNervous system disorders | 8/30 | 11/26 | 8/30 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 6/30 | 6/26 | 9/30 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 5/30 | 4/26 | 9/30 |
| Back painMusculoskeletal and connective tissue disorders | 7/30 | 4/26 | 4/30 |
| Abdominal painGastrointestinal disorders | 3/30 | 5/26 | 3/30 |
| Non-cardiac chest painGeneral disorders | 3/30 | 3/26 | 4/30 |
| PneumoniaInfections and infestations | 2/30 | 2/26 | 4/30 |
| Upper respiratory tract infectionInfections and infestations | 4/30 | 1/26 | 1/30 |
| Urinary tract infectionInfections and infestations | 4/30 | 2/26 | 2/30 |
| Musculoskeletal painMusculoskeletal and connective tissue disorders | 2/30 | 3/26 | 3/30 |
| Age, Continuous(Years) | PLACEBO 10MG BID + PLACEBO 45MG BID | TICAGRELOR 10MG BID + PLACEBO 45MG BID | TICAGRELOR 45MG BID + PLACEBO 10MG BID | Total |
|---|---|---|---|---|
| Mean | 21.6 ± 3.42 | 21.9 ± 2.72 | 23.2 ± 3.69 | 22.2 ± 3.35 |
| Sex: Female, Male(Participants) | PLACEBO 10MG BID + PLACEBO 45MG BID | TICAGRELOR 10MG BID + PLACEBO 45MG BID | TICAGRELOR 45MG BID + PLACEBO 10MG BID | Total |
|---|---|---|---|---|
| Female | 16 | 15 | 16 | 47 |
| Male | 14 | 12 | 14 | 40 |
| Race (NIH/OMB)(Participants) | PLACEBO 10MG BID + PLACEBO 45MG BID | TICAGRELOR 10MG BID + PLACEBO 45MG BID | TICAGRELOR 45MG BID + PLACEBO 10MG BID | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 15 | 14 | 17 | 46 |
| White | 15 | 12 | 13 | 40 |
| More than one race | 0 | 1 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
Ran from Jul 2015 to primary completion in Nov 2016, 16 months.
Results were first posted in Dec 2017, 1 year after primary completion.
Of 34 industry-sponsored phase 2 interventional studies under Anemia, Sickle Cell, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 41. This study's 16 months is below that.
Counting every sponsor, half of 93 studies reached it within 46 months; a quarter within 24 and three quarters within 73.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ticagrelor